Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)
1990

Chemosensitisation by Verapamil and Cyclosporin A in Mouse Tumour Cells

publication Evidence: moderate

Author Information

Author(s): P.R. Twentyman, J.G. Reeve, G. Koch, K.A. Wright

Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, and Laboratory of Molecular Biology, MRC Centre, Cambridge, UK

Hypothesis

The study examines the relationship between drug resistance and the expression of P-glycoprotein and CP22 in mouse tumour cells.

Conclusion

The study found that chemosensitisation by verapamil and cyclosporin A is complex and depends on the sensitiser dose, the cytotoxic agent, and the specific cell line.

Supporting Evidence

  • The study found a correlation between P-glycoprotein levels and drug resistance.
  • Verapamil and cyclosporin A were shown to modify drug sensitivity in multidrug-resistant cell lines.
  • Different levels of P-glycoprotein expression affected the efficacy of the sensitising agents.

Takeaway

This study looks at how two drugs can help make cancer cells more sensitive to treatment, but it’s complicated and depends on many factors.

Methodology

The study used a panel of multidrug-resistant mouse tumour cell lines to assess the effects of verapamil and cyclosporin A on drug resistance.

Potential Biases

Potential bias in the interpretation of results due to the complexity of drug interactions.

Limitations

The study does not provide specific limitations.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication